Yield10 Bioscience Inc
OTC:YTENQ
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Yield10 Bioscience Inc
OTC:YTENQ
|
1 USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
409.8B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
193.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.5B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
84.3B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
72.6B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.1B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Yield10 Bioscience Inc
Glance View
Yield10 Bioscience, Inc. operates as an agricultural bioscience company. The company is headquartered in Woburn, Massachusetts and currently employs 29 full-time employees. The company went IPO on 2006-11-10. The firm is developing the oilseed Camelina sativa (Camelina) as a platform crop for large scale production of low-carbon sustainable seed products. The firm focuses on petroleum replacement markets, in which it is developing Camelina oil for use as a biofuel feedstock and polyhydroxyalkanoates (PHA) bioplastics produced in Camelina seed for use as a biodegradable bioplastic; and food and nutrition markets, in which it is developing omega-3 (DHA+EPA) oils produced in Camelina seed for aquaculture, nutraceuticals and protein meal for animal feed markets. The company is engaged in the development of elite Camelina germplasm exhibiting herbicide tolerance, disease resistance and other traits that form improved elite Camelina varieties for the biofuel market. The firm's new seed product traits include the PHA bioplastic trait developed by the Company and the omega-3 (DHA+EPA) oil traits.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Yield10 Bioscience Inc is -1 678.7%, which is above its 3-year median of -8 159.2%.
Over the last 3 years, Yield10 Bioscience Inc’s Operating Margin has decreased from -1 336.4% to -1 678.7%. During this period, it reached a low of -24 028.3% on Dec 31, 2023 and a high of -1 336.4% on Jun 30, 2021.
